

Contents

Contributors	xv
Foreword: The future of medical discovery	xvii
Preface	xix
Guide and legend	xxi

I

Introduction

1. Introduction	
Terminology of cellular systems	3
Introduction to cell signaling	6
Pathways for systems biology	14
References	28

II

Human disease pathways

2. Infectious diseases	
2.1 Human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS)	37
Key cellular contributors and processes	39
Pathway 1	40
HIV entrance to the host cell and viral reproduction	40
Pathway 2	44
HIV-induced depletion of CD4+ T cells	44
Pathway 3	48
HIV latency	48
References	53
2.2 Human T-cell leukemia virus infection and leukemia progression	55
Key cellular contributors and processes	57
Pathway 1	58
HTLV-1 enters the cell	58
Pathway 2	60
Transcription and reproduction of the HTLV-1 genome	60

Pathway 3	63
Tax-induced aneuploidy in T cells infected with HTLV-1	63
Pathway 4	65
Tax-induced disruption of the G1/S transition in HTLV-1-infected T cells	65
Pathway 5	66
Tax-mediated dysregulation of NF- κ B signaling in HTLV-1 infection	66
Pathway 6	71
p121 viral protein promotes T-cell activation in HTLV-1 infection	71
References	73
2.3 Human papillomavirus infection and cancer	75
Key cellular contributors and processes	77
Pathway 1	78
Human papillomavirus entry into cell	78
Pathway 2	81
Human papillomavirus E1 and E2 proteins in virus replication	81
Pathway 3	84
Human papillomavirus E4 and E5 proteins in viral reproduction	84
Pathway 4	87
Human papillomavirus E6 and E7 proteins promote epithelial cell survival	87
Pathway 5	90
Human papillomavirus E6 and E7 proteins promote epithelial cell proliferation	90
References	93
3. Diseases of the blood	
3.1 Anemia of chronic disease (inflammatory anemia)	97
Key cellular contributors and processes	99
Pathway 1	100
Inflammatory mediators raise the production of hepcidin	100
Pathway 2	102
High levels of hepcidin block iron absorption in the gut	102
Pathway 3	105
Impairment of iron release from splenic macrophages	105
Pathway 4	107
Inflammatory mediators inhibit GATA signaling in erythropoiesis	107
Pathway 5	109
The rationale for anemia of chronic disease treatment with erythropoietin	109
References	111
3.2 Hemophilia	112
Key cellular contributors and processes	115
Pathway 1	116
Dysfunction of the coagulation cascade in hemophilia	116
References	118
4. Endocrine, nutritional, and metabolic diseases	
4.1 Diabetes mellitus type I	124

Key cellular contributors and processes	126
Pathway 1	128
Antigen-presenting cells promote islet dysfunction and immune system activation in T1D	128
Pathway 2	131
Defective tolerance of autoreactive T cells in T1D	131
Pathway 3	135
Islet beta-cell destruction in T1D	135
References	138
4.2 Type 2 diabetes mellitus	140
Key cellular contributors and processes	142
Pathway 1	144
Insulin synthesis	144
Pathway 2	149
Hyperglycemia and hyperlipidemia trigger beta-cell apoptosis	149
Pathway 3	152
Beta-cell proliferation and compensation	152
Pathway 4	159
Insulin resistance	159
References	166
4.3 Diabetic neuropathy	169
Key cellular contributors and processes	171
Pathway 1	172
Microangiopathy in diabetic neuropathy	172
Pathway 2	175
Neuron and Schwann cell death	175
Pathway 3	178
Pain perception in diabetic neuropathy	178
References	181
4.4 Hypothyroidism	182
Key cellular contributors and processes	184
Pathway 1	185
Decreased secretion of thyroid hormones	185
Pathway 2	190
Cellular effects of thyroid hormone deficiency	190
References	197
4.5 Alpha-1 antitrypsin deficiency	199
Key cellular contributors and processes	200
Pathway 1	201
SERPINA1-associated pulmonary emphysema	201
Pathway 2	204
SERPINA1-associated liver damage	204
References	206
4.6 Cystic fibrosis	207
Key cellular contributors and processes	209

Pathway 1	210
CFTR expression and degradation in epithelial cells in cystic fibrosis (class I-II mutations)	210
Pathway 2	213
Failure of the ion channel function of CFTR in cystic fibrosis airway epithelium (class III-IV mutations)	213
References	217
5. Diseases of the nervous system	
5.1 Alzheimer's disease	221
Key cellular contributors and processes	223
Pathway 1	224
Amyloid-beta production and functions in Alzheimer's disease	224
References	231
5.2 Amyotrophic lateral sclerosis	234
Key cellular contributors and processes	236
Pathway 1	237
Glutamate and calcium excitotoxicity of motor neurons in ALS	237
Pathway 2	240
Mutations in SOD1 and associated proteins cause motor neuron death in familial ALS	240
References	244
5.3 Familial hemiplegic migraine (FHM)	246
Key cellular contributors and processes	248
Pathway 1	249
Glutamate overload effects on the activation of prostaglandin E2 and NO synthesis	249
Pathway 2	253
Glutamate overload caused by mutations in the genes associated with familial and sporadic hemiplegic migraine	253
References	257
6. Diseases of the eye	
6.1 Glaucoma	261
Key cellular contributors and processes	263
Pathway 1	264
Trabecular meshwork and Schlemm's canal endothelial cell volume and contractility	264
Pathway 2	267
MYOC-associated glaucoma	267
Pathway 3	269
Role of neurotrophic factor deprivation in retinal ganglion cell death	269
References	271
6.2 Age-related macular degeneration	273
Key cellular contributors and processes	274
Pathway 1	276
Complement activation in age-related macular degeneration	276

Pathway 2	278
Oxidative stress, all-trans-retinal, and lipofuscin toxicity in age-related macular degeneration	278
Pathway 3	281
Endoplasmic reticulum stress in age-related macular degeneration	281
References	283
6.3 Cataract	285
Key cellular contributors and processes	286
Pathway 1	287
Age-related cataract	287
Pathway 2	290
Diabetes-induced cataract	290
Pathway 3	292
Congenital cataract	292
References	295
7. Diseases of the ear	
7.1 Hearing loss	299
Key cellular contributors and processes	300
Pathway 1	302
Dysfunction of cochlear hair cell stereocilia proteins in hearing loss	302
Pathway 2	306
Dysfunctions of cochlear hair cell synapse proteins in hearing loss	306
Pathway 3	309
Impairment of mechanoelectrical transduction and potassium cycling in the inner ear in hearing loss	309
References	312
7.2 Otitis media	315
Key cellular contributors and processes	317
Pathway 1	318
Insufficient activation of immune response in the middle ear epithelium cells in otitis media	318
Pathway 2	321
Pathogens stimulate mucins expression in the middle ear	321
References	324
8. Diseases of the circulatory system	
8.1 Atherosclerosis description	330
Key cellular contributors and processes	332
Pathway 1	333
Low-density lipoprotein internalization and the accumulation of lipids in atherosclerosis	333
Pathway 2	336
Oxidized LDL causes endothelial dysfunction in atherosclerosis	336
Pathway 3	340
Arterial wall inflammation and calcification in atherosclerosis	340
References	343

8.2 Hypertension	345
Key cellular contributors and processes	347
Pathway 1	348
Rise in aldosterone synthesis in adrenal zona glomerulosa cells	348
Pathway 2	351
The role of aldosterone in the regulation of $\text{Na}^+/\text{Cl}^-/\text{K}^+$ homeostasis	351
Pathway 3	354
Dysfunction of smooth muscle cells in hypertension	354
Pathway 4	357
Endothelial cells repress vasoconstriction in hypertension	357
References	360
8.3 Pulmonary arterial hypertension	361
Key cellular contributors and processes	363
Pathway 1	364
Endothelial cells stimulate vasoconstriction and thrombosis in pulmonary hypertension	364
Pathway 2	367
The intense proliferation and contractile activity of smooth muscle cells in pulmonary hypertension	367
Pathway 3	370
Increased proliferation of PASMCs in familial forms of pulmonary hypertension	370
References	373
8.4 Hypertrophic cardiomyopathy	374
Key cellular contributors and processes	375
Pathway 1	376
Sarcomere disorganization and intracellular calcium overload	376
Pathway 2	379
Cardiomyocyte hypertrophy	379
References	381
8.5 Arrhythmogenic right ventricular dysplasia (ARVD)	382
Key cellular contributors and processes	383
Pathway 1	384
Adherens junction dysfunction in cardiomyocytes in ARVD	384
Pathway 2	386
Desmosome dysfunction in cardiomyocytes in ARVD	386
Pathway 3	388
Cardiomyocyte dysfunction unrelated to cell junctions in ARVD	388
References	390
9. Diseases of the respiratory system	
9.1 Asthma	395
Key cellular contributors and processes	395
Pathway 1	397
Th2 cell response in asthma	397
Pathway 2	402
Eosinophilia and neutrophilia in asthma	402

Pathway 3	409
Airway surface liquid thickness and mucus accumulation in asthma	409
Pathway 4	415
Airway smooth muscle cells and airway remodeling in asthma	415
References	420
9.2 Chronic obstructive pulmonary disease	425
Key cellular contributors and processes	427
Pathway 1	430
Cigarette smoke causes dysfunction and production of inflammatory mediators in alveolar epithelial cells	430
Pathway 2	433
Cigarette smoke and inflammation cause alveolar epithelial cell death in COPD	433
Pathway 3	436
Role of alveolar macrophages in pulmonary tissue destruction in COPD	436
Pathway 4	439
Mucin hypersecretion in COPD	439
References	441
10. Diseases of the digestive system	
10.1 Crohn's disease	445
Key cellular contributors and processes	447
Pathway 1	449
Defects in response to pathogens in the gut promotes inflammation in Crohn's disease	449
Pathway 2	453
Enteric cell dysfunction in Crohn's disease	453
Pathway 3	455
Autophagy dysfunction in Crohn's disease	455
References	457
10.2 Ulcerative colitis	459
Key cellular contributors and processes	461
Pathway 1	462
Intestine epithelial cell dysfunction in ulcerative colitis	462
Pathway 2	466
Intestine epithelial cells drive immunological responses in ulcerative colitis	466
Pathway 3	469
Leukocyte migration toward the endothelial cells in the intestine microvasculature	469
Pathway 4	471
Polymorphisms associated with inflammatory bowel diseases	471
References	474
10.3 Celiac disease	476
Key cellular contributors and processes	477
Pathway 1	478
CD4+ T cell and epithelial cell response in celiac disease	478
Pathway 2	481
CD8+ T-cell response and mucosal damage in celiac disease	481
References	483

10.4 Nonalcoholic fatty liver disease	484
Key cellular contributors and processes	485
Pathway 1	486
Triglyceride storage in NAFLD	486
Pathway 2	488
Lipotoxicity in NAFLD	489
References	491
11. Diseases of the skin and subcutaneous tissue	
11.1 Acne vulgaris	495
Key cellular contributors and processes	496
Pathway 1	497
Inflammation in keratinocytes in the pathology of acne	497
Pathway 2	499
Increased proliferation of sebocytes in acne vulgaris	499
Pathway 3	501
Hyperseborrhea in acne vulgaris	501
References	503
11.2 Atopic dermatitis	504
Key cellular contributors and processes	506
Pathway 1	506
The onset of atopic dermatitis	506
Pathway 2	511
Acute phase initiation in atopic dermatitis	511
References	513
11.3 Psoriasis	514
Key cellular contributors and processes	515
Pathway 1	516
Differentiation of psoriatic T cells	516
Pathway 2	518
Interleukin-17 and interleukin-22 signaling in psoriasis	519
References	522
11.4 Ichthyosis	523
Key cellular contributors and processes	524
Pathway 1	525
Ichthyosis vulgaris overview	525
Pathway 2	527
X-linked ichthyosis overview	527
Pathway 3	530
Harlequin ichthyosis overview	530
References	532
12. Diseases of the musculoskeletal system	
12.1 Osteoarthritis	535
Key cellular contributors and processes	537

Pathway 1	538
TNF and IL1B provoke ECM degradation in osteoarthritis	538
Pathway 2	541
Chondrocyte death in osteoarthritis	541
Pathway 3	544
TGFB signaling provokes endochondral ossification with osteophyte formation in OA	544
References	547
12.2 Osteoporosis (type I)	548
Key cellular contributors and processes	549
Pathway 1	550
Osteoclast-mediated bone resorption in postmenopausal women	550
Pathway 2	553
Osteoblast-mediated bone demineralization in postmenopausal women	553
References	556
12.3 Osteopetrosis	557
Key cellular contributors and processes	558
Pathway 1	559
Osteoclast functional impairment in osteopetrosis	559
Pathway 2	563
WNT signaling dysregulation in osteoblasts	563
Pathway 3	565
Renal tubular acidosis associated with carbonic anhydrase II mutation and osteopetrosis	565
References	567
13. Diseases of the genitourinary system	
13.1 Pyelonephritis	572
Key cellular contributors and processes	574
Pathway 1	575
The role of toll-like receptors in pyelonephritis	575
Pathway 2	577
The role of endothelial cells in pyelonephritis	577
Pathway 3	579
The role of interstitial fibroblasts in pyelonephritis	579
References	581
13.2 Glomerulonephritis	582
Key cellular contributors and processes	584
Pathway 1	586
The role of complement in glomerulonephritis	586
Pathway 2	588
Podocyte dysfunction in glomerulonephritis	588
Pathway 3	591
Mesangial cell dysfunction in glomerulonephritis	591
References	593

13.3 Polycystic kidney disease	594
Key cellular contributors and processes	596
Pathway 1	597
Formation cysts in polycystic kidney disease	597
Pathway 2	600
Dysfunction of cilia in polycystic kidney disease	600
References	602
13.4 Polycystic ovary syndrome	603
Key cellular contributors and processes	605
Pathway 1	606
Disruption of luteinizing hormone and follicle-stimulating hormone secretion in PCOS	606
Pathway 2	609
Impaired steroidogenesis in PCOS	609
References	612
13.5 Endometriosis	613
Key cellular contributors and processes	615
Pathway 1	616
Local estrogen production stimulates ectopic endometrium proliferation	616
Pathway 2	619
Progesterone resistance stimulates endometriotic cell survival	619
Pathway 3	622
Enhanced angiogenesis in endometriosis	622
References	624

III

Pathway analysis perspectives/advantages

14. Applications of disease pathways in biology and medicine

Pathway analysis for personalized medicine	632
Bioinformatics foundation for patient data analysis	636
Pathway and network analysis output interpretation	648
In silico modeling in biomedicine	652
Tools and repositories for pathway analysis	656
Conclusion	659
References	660

Glossary and index	669
---------------------------	-----

Links	681
--------------	-----

Index	687
--------------	-----